Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker REGN · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Aug 31, 2026 | LIBTAYO CEMIPLIMAB-RWLC | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761097 ↗ |
| Aug 19, 2026 | PASATRU GARETOSMAB-GRTS | REGN Regeneron Pharmaceuticals, Inc | Biologic (BLA) Type 1 - New Molecular Entity | BLA761508 ↗ |
| Jul 31, 2026 | LYNOZYFIC LINVOSELTAMAB-GCPT | REGN Rengeneron Pharmaceuticals, Inc. | Biologic (BLA), supplement REMS | BLA761400 ↗ |
| Jul 15, 2026 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ |
| Apr 22, 2026 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| Apr 16, 2026 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ |
| Apr 2, 2026 | EYLEA HD AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761355 ↗ |
| Feb 23, 2026 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| Nov 19, 2025 | EYLEA HD AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761355 ↗ |
| Oct 29, 2025 | LIBTAYO CEMIPLIMAB-RWLC | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761097 ↗ Letter or label ↗ |
| Oct 9, 2025 | PRALUENT ALIROCUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA125559 ↗ |
| Oct 8, 2025 | LIBTAYO CEMIPLIMAB-RWLC | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761097 ↗ |
| Sep 25, 2025 | EVKEEZA EVINACUMAB-DGNB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761181 ↗ |
| Jul 2, 2025 | LYNOZYFIC LINVOSELTAMAB-GCPT | REGN Rengeneron Pharmaceuticals, Inc. | Biologic (BLA) Type 1 - New Molecular Entity | BLA761400 ↗ |
| Jun 18, 2025 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| Apr 17, 2025 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ Letter or label ↗ |
| Apr 16, 2025 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ Letter or label ↗ |
| Oct 24, 2024 | INMAZEB ATOLTIVIMAB; ODESIVIMAB; MAFTIVIMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761169 ↗ |
| Oct 10, 2024 | EYLEA HD AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761355 ↗ |
| Oct 10, 2024 | EYLEA AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA125387 ↗ |
| Sep 27, 2024 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| Sep 12, 2024 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| Apr 12, 2024 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ |
| Apr 5, 2024 | LIBTAYO CEMIPLIMAB-RWLC | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761097 ↗ |
| Mar 8, 2024 | PRALUENT ALIROCUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA125559 ↗ |
| Mar 6, 2024 | LIBTAYO CEMIPLIMAB-RWLC | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761097 ↗ |
| Jan 25, 2024 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| Jan 12, 2024 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| Dec 14, 2023 | EYLEA HD AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761355 ↗ |
| Dec 14, 2023 | EYLEA AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA125387 ↗ |
| Sep 29, 2023 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ |
| Aug 18, 2023 | EYLEA HD AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA) Type 5 - New Formulation or New Manufac… | BLA761355 ↗ Letter or label ↗ |
| Aug 18, 2023 | VEOPOZ POZELIMAB-BBFG | REGN Regeneron Pharmaceuticals | Biologic (BLA) Type 1 - New Molecular Entity | BLA761339 ↗ Letter or label ↗ |
| Jul 14, 2023 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ |
| Apr 28, 2023 | LIBTAYO CEMIPLIMAB-RWLC | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761097 ↗ |
| Apr 28, 2023 | LIBTAYO CEMIPLIMAB-RWLC | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761097 ↗ |
| Mar 21, 2023 | EVKEEZA EVINACUMAB-DGNB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761181 ↗ |
| Feb 8, 2023 | EYLEA AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA125387 ↗ |
| Nov 8, 2022 | LIBTAYO CEMIPLIMAB-RWLC | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761097 ↗ |
| Oct 17, 2022 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ Letter or label ↗ |
| Sep 28, 2022 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| Sep 6, 2022 | EYLEA AFLIBERCEPT | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA125387 ↗ |
| Jun 7, 2022 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ |
| May 20, 2022 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ Letter or label ↗ |
| May 13, 2022 | INMAZEB ATOLTIVIMAB; ODESIVIMAB; MAFTIVIMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761169 ↗ |
| Dec 22, 2021 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ Letter or label ↗ |
| Dec 22, 2021 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ Letter or label ↗ |
| Dec 22, 2021 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ Letter or label ↗ |
| Oct 20, 2021 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Efficacy | BLA761055 ↗ Letter or label ↗ |
| Oct 1, 2021 | DUPIXENT DUPILUMAB | REGN Regeneron Pharmaceuticals | Biologic (BLA), supplement Labeling | BLA761055 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:30 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates